Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Quoin Pharmaceuticals to post earnings of ($0.50) per share for the quarter.
Quoin Pharmaceuticals Trading Up 2.1 %
Shares of Quoin Pharmaceuticals stock opened at $0.30 on Wednesday. The firm has a market capitalization of $1.51 million, a PE ratio of -0.07 and a beta of 1.82. Quoin Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $1.57. The firm’s 50-day moving average price is $0.41 and its 200 day moving average price is $0.56.
Insider Activity at Quoin Pharmaceuticals
In other Quoin Pharmaceuticals news, CFO Gordon Dunn acquired 122,221 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the acquisition, the chief financial officer now owns 151,077 shares in the company, valued at approximately $67,984.65. The trade was a 423.55 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Anthony James Culverwell acquired 100,000 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $0.45 per share, with a total value of $45,000.00. Following the acquisition, the director now owns 100,317 shares in the company, valued at $45,142.65. The trade was a 31,545.74 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 777,777 shares of company stock valued at $350,000. 3.70% of the stock is owned by corporate insiders.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
Further Reading
- Five stocks we like better than Quoin Pharmaceuticals
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- There Are Different Types of Stock To Invest In
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What is the MACD Indicator and How to Use it in Your Trading
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
